Calendar Year Performance 2014Calendar Year Performance 2015Calendar Year Performance 2016Calendar Year Performance 2017Calendar Year Performance 2018Calendar Year Performance 2019Calendar Year Performance 2020Calendar Year Performance 2021Calendar Year Performance 2022Calendar Year Performance 2023
-
-
-
+ 0.9 %
- 9.0 %
+ 37.8 %
+ 19.6 %
+ 22.5 %
- 20.6 %
+ 15.3 %
Net Asset Value
190.31 €
Asset Under Management
965 M €
Market
European market
SFDR - Fund Classification
Article
9
Data as of: 30 Aug 2024.
Data as of: 5 Sep 2024.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged. The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.
In July, there was a significant stock market rotation, with the European market experiencing a decline.
Despite the ECB’s interest rate cuts in June, prompted by a gradual decline in inflation that has boosted optimism, European equities dipped as earnings in the Technology and Luxury goods sectors dragged on returns.
The technology sector was notably weak, influenced by negative sentiment from sharp declines in Tesla and other Magnificent Seven stocks in the US, while the demand in luxury goods especially in China weighed on results.
Performance commentary
During the month of July, the Fund recorded a positive absolute performance, though below its reference indicator.
The underperformance versus the benchmark last month is mainly due to the market rotation to small cap companies and the rally in Banks which we do not hold in our portfolio.
Lonza and Argenx have been the two best performers in the fund after both reported strong quarterly results and provided an optimistic outlook, which benefited the Fund.
Our biggest detractor during the month has been Novo Nordisk which experienced a significant decline during the month.
The decline was mainly due to the ongoing momentum unwind and news of competition from rival company Roche, who released early data on an oral GLP-1 product.
Having no exposure to Communication Services penalised the Fund while, on the contrary, having no exposure to Energy has been supportive.
Outlook strategy
During the month we have made several adjustments to our portfolio. We significantly reduced our holdings in high momentum stocks, including SAP, Schneider, ASML, and Novo Nordisk.
On the other hand, we made small additions to Healthcare stocks that have been underperforming recently, such as Straumann and Beiersdorf and Demant.
The Fund continues to rely on bottom-up fundamental analysis with a medium-long term horizon.
As rate cuts have started in Europe and the economies weaken, we are encouraged that markets should be able to ride out a period of weaker economic strength and some political headlines.
We stick to our process of focusing on profitable companies with high returns on capital, reinvesting for growth and maintain our focus on stocks and sectors with strong visibility on sales and profits.
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.
Unsupported browserWe've noticed that your browser is no longer supported. To ensure optimal performance and security while using our website, we recommend updating your browser or other relevant software. Thank you for your understanding!
Market environment